Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Update

by · The Cerbat Gem

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT – Get Free Report) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totaling 3,245 shares, a growth of 107.0% from the June 15th total of 1,568 shares. Based on an average daily volume of 59,123 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on XTNT shares. BTIG Research reaffirmed a “buy” rating and set a $1.00 price target on shares of Xtant Medical in a research note on Wednesday, May 13th. Craig Hallum reissued a “buy” rating on shares of Xtant Medical in a research note on Wednesday, March 18th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Xtant Medical currently has an average rating of “Buy” and a consensus target price of $1.00.

Get Our Latest Research Report on XTNT

Xtant Medical Stock Down 0.9%

Shares of Xtant Medical stock traded down $0.00 during midday trading on Thursday, reaching $0.44. 39,711 shares of the company’s stock traded hands, compared to its average volume of 87,850. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.64 and a current ratio of 3.34. Xtant Medical has a 52 week low of $0.39 and a 52 week high of $0.95. The company’s 50 day simple moving average is $0.45 and its 200 day simple moving average is $0.54. The company has a market cap of $62.14 million, a price-to-earnings ratio of 44.34 and a beta of -0.16.

Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02). Xtant Medical had a net margin of 1.50% and a return on equity of 3.68%. The firm had revenue of $20.88 million during the quarter, compared to analysts’ expectations of $20.16 million.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in Xtant Medical during the second quarter valued at approximately $26,000. Mink Brook Asset Management LLC lifted its stake in shares of Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after buying an additional 60,997 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Xtant Medical by 7.3% in the first quarter. Renaissance Technologies LLC now owns 987,410 shares of the medical device company’s stock worth $551,000 after buying an additional 67,550 shares during the last quarter. Tradition Wealth Management LLC bought a new stake in shares of Xtant Medical during the 4th quarter worth $79,000. Finally, Wiregrass Investment Management LLC bought a new stake in shares of Xtant Medical during the 4th quarter worth $81,000. 69.33% of the stock is owned by institutional investors.

Xtant Medical Company Profile

(Get Free Report)

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.

See Also